Richard Klar
0000-0001-6625-794X
Publication & Citation Trends
Publications
0 total
Human angiotensin converting enzyme 2 specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants.
Cited by 3
Semantic Scholar
Strong single-agent and PD-1/PD-L1 combination antitumor activity of antisense oligonucleotides suppressing Neuropilin 1 expression.
Cited by 0
Semantic Scholar
Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides
Cited by 3
Semantic Scholar
Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
Cited by 7
Semantic Scholar
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity OA
Cited by 19
Semantic Scholar
881 Knockdown of neuropilin-1 by third generation antisense oligonucleotides has strong antitumor activity that can be further increased by combination with immune checkpoint inhibitors OA
Cited by 0
Semantic Scholar
Abstract 4149: Knock-down of Neuropilin-1 by locked nucleic acid antisense oligonucleotides facilitates cancer immune control
Cited by 0
Semantic Scholar
Research Topics
CAR-T cell therapy research
(31)
Immunotherapy and Immune Responses
(23)
Cancer Immunotherapy and Biomarkers
(13)
Angiogenesis and VEGF in Cancer
(10)
Immune Cell Function and Interaction
(9)
Affiliations
CGIAR
German Cancer Research Center
Klinikum rechts der Isar
Hikma Pharmaceuticals (Germany)
St. Hedwig-Krankenhaus